What is Achiko?
Achiko operates at the intersection of biotechnology and digital health, focusing on the development of rapid, affordable diagnostic testing. Through its AptameX division, the company utilizes DNA aptamer-based technology, which is chemically synthesized to provide a scalable alternative to traditional diagnostic methods. This hardware innovation is seamlessly integrated with Teman Sehat, a digital mobile health application that serves as a passport solution for health management. By combining these capabilities, Achiko addresses critical gaps in the diagnostic field, particularly for pathogenic diseases. Headquartered in Zurich with a robust presence in Hong Kong, Jakarta, Seoul, and Singapore, the company is strategically positioned to navigate the complexities of global healthcare markets while maintaining a focus on user-centric digital health solutions.
How much funding has Achiko raised?
Achiko has raised a total of $19.3M across 3 funding rounds:
Share Placement
$5.3M
Debt
$12.7M
Debt
$1.3M
Share Placement (2021): $5.3M, investors not publicly disclosed
Debt (2022): $12.7M led by Riverfort Global Opportunities PCC
Debt (2022): $1.3M supported by Buranto and Negma Group
Key Investors in Achiko
Buranto
Buranto is a smart investment firm that provides financial planning and growth strategies for individual investors and small businesses.
Negma Group
Negma Group is a diversified investment fund specializing in debt and equity financing, venture capital, and quantitative trading strategies for high-growth enterprises.
Riverfort Global Opportunities PCC
Riverfort Global Opportunities PCC is an investment vehicle focused on providing strategic debt financing to support the growth and operational requirements of emerging companies.
What's next for Achiko?
Looking ahead, Achiko is poised to leverage its recent capital infusion to accelerate the commercialization of its diagnostic pipeline. The strategic focus will likely center on expanding the reach of the AptameX platform and enhancing the functionality of the Teman Sehat application to meet the growing demand for integrated health monitoring. As the company transitions into its next phase of growth, the emphasis will remain on scaling operations and securing further market penetration for its proprietary technologies. Investors will be closely monitoring the firm's ability to convert its technological advancements into sustainable revenue streams, particularly as it navigates the competitive landscape of global healthtech innovation and diagnostic infrastructure.
See full Achiko company page
